trending Market Intelligence /marketintelligence/en/news-insights/trending/xux4h5wr76zjxzztqdxnua2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Innate Immunotherapeutics changes name to Amplia Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Innate Immunotherapeutics changes name to Amplia Therapeutics

Innate Immunotherapeutics Ltd. is changing its name to Amplia Therapeutics Ltd.

The Australian pharmaceutical company will also change its stock code to ATX from IIL. Shareholders approved the changes at their annual general meeting in August.

The company said the changes are part of a wider branding refresh, as it focuses on therapeutic targets called focal adhesion kinase inhibitors. These can sensitize certain tumors to cancer drugs and chemotherapies.

Recently, the company found itself at the center of a U.S. congressman's insider trading scandal.